Today, William Chin and Cameron Hurst commented about whether ETFC-Q, EW-N, GOOG-Q, BABA-N, MCHP-Q, AMAT-Q, IR-N, CBS-N, META-Q, MIC-N, WFC-N, BAC-N, TJX-N, BX-N, DIS-N, CVS-N, MSFT-Q, NWL-N, AFN-T, CHR-T, GIB.A-T, EMP.A-T, ATS-T, GIB.A-T, NPI-T, XOM-N, IMO-T, HBC-T, CTC.A-T, ATRL-T, AAPL-Q, SLB-N, META-Q, ATL-T, CVE-T, AQN-T, ENB-T, AMZN-Q, CM-T, TECK.B-T are stocks to buy or sell.
This company helps customer to automate their processes to help them be more competitive. It has a new CEO who is very focused on execution. The market believes they will increase profit margins by 5%. They also have a pipeline of acquisitions. The stock now has momentum. Yield 0%. (Analysts’ price target is $18.70 )
This company owns Sobeys’, who acquired Safeway. They have turned things around and “Project Sunrise” is working to centralize things. Same-store traffic and margins are improving. They are doing very well in a very competitive sector. The stock now has momentum. Yield 1.7%. (Analysts’ price target is $28.28 )
He's been hard on this name. He's steered away from consumer staples, a bad neighbourhood. Its retail end has done OK due to consistent demand, but its pharmacy side has struggled. Generic drug pricing pressure is merely one factor. Its dividend isn't enough to make him buy. He could see a pullback when rates rise; inflation hurts bond proxies like this.
This is facing a big sideways consolidation that is spending too much time going without making new highs he says. It shows no signs of breaking out.